Hematopoiesis News and Research RSS Feed - Hematopoiesis News and Research

BCC Research report provides detailed analyses of global stem cell market

BCC Research report provides detailed analyses of global stem cell market

Reportlinker.com announces that a new market research report is available in its catalogue: The Global Market for Stem Cells. [More]
New mouse model supports transplantation of human blood stem cells without need for irradiation

New mouse model supports transplantation of human blood stem cells without need for irradiation

A novel mouse model allows for the transplantation of human blood-forming stem cells without the need for irradiation therapy.For many years scientists have been trying to unravel mechanisms that guide function and differentiation of blood stem cells, those cells that generate all blood cells including our immune system. [More]
Discovery points the way to potential new strategies to treat blood disorders

Discovery points the way to potential new strategies to treat blood disorders

Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, an Indiana University-led research team has reported. [More]
Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014. [More]
Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. [More]
Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting. [More]
New technique expands number of functional cord blood stem cells for transplantation

New technique expands number of functional cord blood stem cells for transplantation

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation. [More]
Einstein faculty members present recent research at AACR Annual Meeting

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year. [More]
Research pinpoints location of key genetic regulators in blood cells

Research pinpoints location of key genetic regulators in blood cells

Research published online today in Blood, the Journal of the American Society of Hematology, presents an unprecedented look at five unique blood cells in the human body, pinpointing the location of key genetic regulators in these cells and providing a new tool that may help scientists to identify how blood cells form and shed light on the etiology of blood diseases. [More]
Researchers evaluate influence of gut microbes on function of immune cells

Researchers evaluate influence of gut microbes on function of immune cells

New research suggests that gut microorganisms do not merely influence immune cell function, but also support the production of immune cells that form the first line of defense against infection. [More]
Gut bacteria and blood cell development relationship helps immune system fight infection

Gut bacteria and blood cell development relationship helps immune system fight infection

The human relationship with microbial life is complicated. At almost any supermarket, you can pick up both antibacterial soap and probiotic yogurt during the same shopping trip. [More]
Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9. [More]
Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. [More]
Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. [More]
Researchers identify potential therapeutic target in treatment of certain AML

Researchers identify potential therapeutic target in treatment of certain AML

Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML. [More]
Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. [More]
Mount Sinai researchers produce cells that resemble hematopoietic stem cells

Mount Sinai researchers produce cells that resemble hematopoietic stem cells

By transferring four genes into mouse fibroblast cells, researchers at the Icahn School of Medicine at Mount Sinai have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. [More]
Discovery of impaired molecular pathway may help treat children with leukemia

Discovery of impaired molecular pathway may help treat children with leukemia

Through genetic engineering of laboratory models, researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center have uncovered a vulnerability in the way cancer cells diverge from normal regenerating cells that may help treat children with leukemia as reported in the journal PNAS on June 3, 2013. [More]
LMU researchers reveal link between natural killer cells and hematopoiesis

LMU researchers reveal link between natural killer cells and hematopoiesis

Infections can trigger hematopoiesis at sites outside the bone marrow - in the liver, the spleen or the skin. Researchers at Ludwig-Maximilians-Universitaet in Munich now show that a specific type of immune cell facilitates such "extra medullary" formation of blood cells. [More]
Research findings have important implications for developmental and cancer biology

Research findings have important implications for developmental and cancer biology

Researchers from Huntsman Cancer Institute at the University of Utah have discovered that while the genes provided by the father arrive at fertilization pre-programmed to the state needed by the embryo, the genes provided by the mother are in a different state and must be reprogrammed to match. [More]